ACCESSION THERAPEUTICS LIMITED
Desconocido
INVECTA: Integrative characterisation of Novel adenovirus VECtors aimed at Therapeutic Applications
ACCESSION THERAPEUTICS LIMITED
participó en un
HORIZON EUROPE:
HORIZON-MSCA-2022-SE-01
Adenovirus based vectors have potential translational and commercial values and are studied as vectors for gene transfer and vaccination . L...
2023-09-22 - 2027-11-30 | Financiado
2023-09-22 - 2027-11-30 | Financiado
* No se disponen de datos de la empresa actual.